A Study to Evaluate ALN-6222 in Participants With Obesity
ConditionObesity
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAlnylam Pharmaceuticals
About this trial
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
Eligibility criteria
Qualifiers
Is an adult patient with a body mass index ≥30 kg/m² to <40 kg/m²
Has a hemoglobin A1c <6.5%
Disqualifiers
Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN)
Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
Has an estimated glomerular filtration (eGFR) of <60 mL/min/1.73m² at screening
Trial design
Treatments tested in this trial
- ALN-6222
- Placebo
Treatment groups
88 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov